v3.26.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Research and development expenses $ 3,704,753 $ 4,968,596 $ 15,557,617 $ 14,477,204
Acquisition-related costs   167,929   3,673,954
General and administrative expenses 1,956,008 1,593,078 6,396,327 5,471,424
Operating Loss (5,660,761) (6,729,603) (21,953,944) (23,622,582)
Other (Expense) Income:        
Grant income   138,299   713,508
Interest expense (752,509) (16,532) (1,248,117) (16,532)
Interest income 3,685 6,060 32,580 135,624
Other expense   (185,019)   (185,019)
Change in fair value of Kineta merger holdback shares   (315,660)   (315,660)
Total Other (Expense) Income (748,824) (372,852) (1,215,537) 331,921
Net Loss (6,409,585) (7,102,455) (23,169,481) (23,290,661)
Series A Preferred cash dividend (2,089) (2,089) (6,267) (6,267)
Net Loss attributable to common stockholders $ (6,411,674) $ (7,104,544) $ (23,175,748) $ (23,296,928)
Net Loss per share, basic $ (0.1) $ (0.14) $ (0.37) $ (0.5)
Net Loss per share, diluted $ (0.1) $ (0.14) $ (0.37) $ (0.5)
Weighted-average shares outstanding, basic 64,998,838 50,666,430 63,009,136 46,235,423
Weighted-average shares outstanding, diluted 64,998,838 50,666,430 63,009,136 46,235,423